ANTITUMOR-ACTIVITY AND MECHANISM OF ACTION OF THE NOVEL MARINE NATURAL-PRODUCTS MYCALAMIDE-A AND MYCALAMIDE-B AND ONNAMIDE
- 1 June 1989
- journal article
- research article
- Vol. 49 (11) , 2935-2940
Abstract
Three novel heterocyclic compounds, mycalamide-A and -B and onnamide, were isolated from Mycale sp. and Theonella sp. sponges collected in New Zealand and Okinawan waters. Each inhibited potent in vitro toxicity and in vivo efficacy against murine and human tumor cells. Concentration of each that inhibited replication of cultured murine lymphoma P388 cells by 50% were 5 mM or less. Mycalamide-A and -B were also potent inhibitors of HL-60, HT-29, and A549 human tumor cell replication (50% inhibitory concentration < 5 nM), while values for onnamide were greater (50% inhibitory concentrations between 25 and 200 nM). Mycalamide-A (10 .mu.g/kg) and -B (2.5 .mu.g/kg) were moderately active against P388 leukemia (increase in life span, approximately 50%), while onnamide was inactive (40 .mu.g/kg; increase in life span, 15%). Mycalamide-A was also active against B16 melanoma, Lewis lung carcinoma, M5076 ovarian sarcoma, colon 26 carcinoma, and the human MX-1 CX-1, and Burkitt''s lymphoma tumor xenografts. Mechanism of action studies indicate that the three agents inhibited protein synthesis. For example, after 1-h exposures to 20 nM mycalamide-A and -B, the rates of [3H]leucine incorporation into acid-precipitable material of cultured P388 cells were inhibited 54 and 99%, while the effects on incorporation of [3H]uridine and [3H]thymidine were less. The relative effects of 20 to 2000 nM mycalamide-A on protein, RNA, and DNA synthesis were consistent with those observed during exposure of P388 cells to 1 .mu.M emetine, a known inhibitor of protein synthesis. Also, the three agents inhibited translation of RNA into protein in a cell-free lysate of rabbit reticulocytes. Although mycalamide-A disrupted DNA metabolism, the agent apparently did not intercalate into DNA, and a mixture of four effects of the agent. Collectively, these data indicate that this case of compounds represents novel antitumor agents which should be further evaluated to define their potential.This publication has 11 references indexed in Scilit:
- Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells.Proceedings of the National Academy of Sciences, 1987
- A Clinical Trial of Homoharringtonine in the Treatment of Advanced Breast CancerTumori Journal, 1986
- Phase II Evaluation of Anguidine (NSC 141537) in 5-Day Courses in Colorectal Adenocarcinoma A Southeastern Cancer Study Group TrialAmerican Journal of Clinical Oncology, 1986
- CLINICAL PREDICTIVITY OF TRANSPLANTABLE TUMOR SYSTEMS IN THE SELECTION OF NEW DRUGS FOR SOLID TUMORS - RATIONALE FOR A 3-STAGE STRATEGY1983
- Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean TunicateScience, 1981
- Mutations in the gene coding for Escherichia coli DNA topoisomerase I affect transcription and transposition.Proceedings of the National Academy of Sciences, 1981
- Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL‐60) by compounds which induce differentiation of murine leukemia cellsInternational Journal of Cancer, 1980
- Biochemical Parameters of Resistance of an Adriamycin-Resistant Subline of P388 Leukemia to Emetine, an Inhibitor of Protein SynthesisJNCI Journal of the National Cancer Institute, 1978
- In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stainExperimental Cell Research, 1977
- New Human Tumor Cell LinesPublished by Springer Nature ,1975